Related Experiment Video
Updated: Mar 1, 2026
09:30
Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
4.6K
Pharmaceutical Approval Update
Abstract:
Ribociclib (Kisqali) for HR+/HER2- advanced or metastatic breast cancer in postmenopausal women; safinamide (Xadago) as adjunctive treatment for patients with Parkinson's disease; and avelumab (Bavencio) for metastatic Merkel cell carcinoma.
Insights
New drug approvals offer advanced treatment options for patients. Kisqali targets HR+/HER2- metastatic breast cancer, Xadago aids Parkinson
Area of Science:
- Oncology
- Neurology
Background:
- Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer presents treatment challenges.
- Parkinson's disease management requires effective adjunctive therapies.
- Metastatic Merkel cell carcinoma has limited treatment options.
Purpose of the Study:
- To evaluate the efficacy and safety of Ribociclib (Kisqali) in postmenopausal women with HR+/HER2- advanced or metastatic breast cancer.
- To assess the utility of Safinamide (Xadago) as an add-on therapy for Parkinson's disease patients.
- To determine the effectiveness of Avelumab (Bavencio) in treating metastatic Merkel cell carcinoma.
Main Methods:
- Clinical trials were conducted to assess treatment outcomes.
- Patient responses and adverse events were meticulously monitored.
- Data analysis focused on efficacy endpoints and safety profiles.
Main Results:
- Ribociclib demonstrated efficacy in HR+/HER2- advanced or metastatic breast cancer.
- Safinamide showed benefits as adjunctive treatment for Parkinson's disease.
- Avelumab proved effective for metastatic Merkel cell carcinoma.
Conclusions:
- Ribociclib (Kisqali) is a new option for HR+/HER2- advanced or metastatic breast cancer.
- Safinamide (Xadago) offers a new adjunctive treatment for Parkinson's disease.
- Avelumab (Bavencio) provides a treatment for metastatic Merkel cell carcinoma.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
293
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
293
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
01:28Drug Products: Biologics, Biosimilars and Interchangeables
312
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
312
01:25Drug Regulation
3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
01:26Drug Administration and Therapy Phases: Overview
1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
01:11Clinical Trials: Overview
5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K